News from the PREFER project
PREFER on twitter
- .@IMI_PREFER @DrugInfoAssn Speaking today at the #DIA2018 special session on the role of Patients as collaborators in Research #PREFER #ECPC.pic.twitter.com/Hd1d2T45L5 2018-04-17 11:46
- Curious about the #HTA perspective in @IMI_PREFER? Find out what Irina Cleemput from @KCEfgov has to say about seeing #patientpreferences through a public eye.pic.twitter.com/ouEw4o4V2X 2018-04-10 12:26
- How can #rheumatoidarthritis #patientpreferences add value when regulators make decisions on drug development? Read what Karin Schölin Bywall has to say about her PhD project and @IMI_PREFER https://bit.ly/2uuwGdx pic.twitter.com/eUbfIYsLtx 2018-03-29 15:20
We are developing evidence-based recommendations to guide industry, regulatory authorities, HTA bodies, reimbursement agencies, and health care professionals. We start with work to assess methodologies. After that, we test them in clinical case studies. This work will be the basis for the recommendations we make.
Together with stakeholders
PREFER is a public-private partnership with collaboration at every level, making sure we get more than one perspective on everything we do. We have stakeholder partners from Health Technology Assessment bodies and patient organisations. We are also working closely with regulators to ensure recommendations are evidence based, relevant and useful.
Patient preferences through a public eye
For patient preferences to be useful in decision-making processes, they have to be measured in a valid and reliable way. However, to be successful, the methods recommended by PREFER also have to be user-friendly and affordable.
Apart from risk-benefit balance of treatments, HTA has many more additional considerations when preparing for a reimbursement decision. Here, Irina Cleemput, public co-lead for recommendations, shares the HTA perspective and her view on how it is represented in PREFER.
Challenges and opportunities in patient preference assessment
Patient preferences are taking on an increasingly important role in the lifecycle of medical products. The methods to assess preferences are many, and PREFER will contribute knowledge on which methods are best suited at different points. As part of his PhD project, Vikas Soekhai will help identify methods and simulate the impact the choice of method may have on preference study results.
Vikas Soekhai's PhD will contribute to PREFER knowledge on the challenges and opportunities involved in assessments of patient preferences throughout the whole lifecycle of drugs and medical devices.
PREFER PhD project on rheumatoid arthritis
In March this year, Karin Schölin Bywall started her PhD studies at Uppsala University. Her project is part of PREFER. It will look at how rheumatoid arthritis patient preferences can add value when regulators make decisions on drug development.
According to Karin Schölin Bywall, the PREFER project offers the chance to work with PhD students from other universities. PREFER also allows her to develop research questions with senior researchers from universities and the pharmaceutical industry. This collaboration also ensures stakeholder perspectives in her PhD project.
Finding out what patients prefer
Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when and where patients want, can, and should be involved in drug development.
We are looking forward to sharing our findings with you!
Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader
Innovative Medicines Initiative
PREFER is funded by the Innovative Medicines Initiative (IMI): a part of the EU Horizon 2020 Programme.
The academic research in PREFER is funded by Horizon 2020: the EU Framework Programme for Research and Innovation.
The pharmaceutical industry contributes equally to the PREFER project. Industry input to the IMI programme is organised by EFPIA.